MedTrace Logo

Experience in Borderline Ovarian Tumors

NCT05791838 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2023-03-30

No results posted yet for this study

Summary

Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent an independent disease entity among epithelial ovarian cancers. The present study aimed to report the 8-year experience of a single center on the management and outcomes of consecutive BOTs patients. From January 2010 to December 2017, all patients with BOTs undergoing surgical treatment were included. Demographic, clinical, and pathological data were reviewed retrospectively.

Conditions

  • Borderline Ovarian Tumor

Sponsors & Collaborators

  • University of Palermo

    lead OTHER

Principal Investigators

  • Basilio Pecorino, M.D. · University of Catania

  • Paolo Scollo, M.D. Ph.D. · University of Catania

  • Antonio Simone Laganà, M.D. Ph.D. · University of Palermo

  • Andrea Etrusco, M.D. · University of Palermo

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2023-03-31
Completion
2023-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05791838 on ClinicalTrials.gov